Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis

NCT05642468 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped Due to Sponsor decision, not due to any safety concerns

Conditions

Primary Sclerosing Cholangitis

Interventions

DRUG: Ritivixibat

Sponsor

Albireo, an Ipsen Company